FibroGen, Inc (FGEN) Dividend History

Company News

• Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

  AstraZeneca has acquired FibroGen's Chinese subsidiary for $160 million, strengthening its position in the Chinese market and enabling FibroGen to focus on its pipeline development in the US.

  Benzinga
• Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030

  The global liver fibrosis market is expected to grow from $17.25 billion in 2021 to $43.98 billion by 2030, driven by the increasing prevalence of liver disorders, adaptation of unhealthy lifestyles, and the rising geriatric population. The North American region dominates the market due to high healthcare expenditure and the presence of major players.

  GlobeNewswire Inc.

  Featured Companies: BMY DVAX GILD JNJ MRK PFE VRTX
• Catalyst Accelerator Ogden Selects 11 Companies for Fall 2024 Cohort in Partnership with the Department of the Air Force Digital Transformation Office

  The Catalyst Accelerator Ogden, in collaboration with the Department of the Air Force Digital Transformation Office, has selected 11 innovative small businesses to address the Air Force's digital modernization challenges through cutting-edge technologies in areas such as AI/ML, data fusion, automation, and cybersecurity.

  GlobeNewswire Inc.

  Featured Companies: CCTG CGTX FTEK
• FibroGen Stock Is Surging After The Bell: What's Going On?

  FibroGen Inc (NASDAQ:FGEN) shares are moving higher in Monday’s after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) for FG-3165. The company also announced a new clinical trial supply agreement with Regeneron. What Happened: After the market close on Monday, FibroGen said the FDA cleared its IND of FG-3165, allowing the company to initiate a Phase 1 clinical trial. FG-3165 is a galectin-9 targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression. Phase 1 trials evaluating the safety ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: REGN
• FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

  SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.

  GlobeNewswire Inc.